AI Proteins
AI Proteins designs and develops novel miniprotein therapeutics to create durable, specific, and manufacturable drug candidates. It uses a proprietary platform that combines artificial intelligence, computational protein design, synthetic biology, robotics and automation with structural biology, yeast and phage display, and biochemical screening to generate and optimize de novo miniproteins. The company operates as a biotechnology developer and partner, offering research collaborations, licensing and SaaS-like capabilities to biotechnology and pharmaceutical customers while advancing an internal oncology pipeline. AI Proteins targets therapeutic areas such as oncology, inflammation and metabolic disease and aims to accelerate progression of lead candidates toward IND‑enabling studies through integrated design and high‑throughput discovery.
AI Proteins
AI Proteins designs and develops novel miniprotein therapeutics to create durable, specific, and manufacturable drug candidates. It uses a proprietary platform that combines artificial intelligence, computational protein design, synthetic biology, robotics and automation with structural biology, yeast and phage display, and biochemical screening to generate and optimize de novo miniproteins. The company operates as a biotechnology developer and partner, offering research collaborations, licensing and SaaS-like capabilities to biotechnology and pharmaceutical customers while advancing an internal oncology pipeline. AI Proteins targets therapeutic areas such as oncology, inflammation and metabolic disease and aims to accelerate progression of lead candidates toward IND‑enabling studies through integrated design and high‑throughput discovery.